These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 27246234)
41. Fosfomycin trometamol in the prophylaxis of post-kidney transplant urinary tract infection: A controlled, randomized clinical trial. Arreola-Guerra JM; Rosado-Canto R; Alberú J; Maravilla E; Torres-González P; Criollo E; Pérez M; Mancilla E; Arvizu M; Morales-Buenrostro LE; Vilatobá-Chapa M; Sifuentes-Osornio J Transpl Infect Dis; 2018 Oct; 20(5):e12980. PubMed ID: 30133928 [TBL] [Abstract][Full Text] [Related]
42. Progressive increase of resistance in Enterobacteriaceae urinary isolates from kidney transplant recipients over the past decade: narrowing of the therapeutic options. Origüen J; Fernández-Ruiz M; López-Medrano F; Ruiz-Merlo T; González E; Morales JM; Fiorante S; San-Juan R; Villa J; Orellana MÁ; Andrés A; Aguado JM Transpl Infect Dis; 2016 Aug; 18(4):575-84. PubMed ID: 27373698 [TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints. Abbott IJ; Mouton JW; Peleg AY; Meletiadis J J Antimicrob Chemother; 2021 Nov; 76(12):3201-3211. PubMed ID: 34473271 [TBL] [Abstract][Full Text] [Related]
44. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series. Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609 [TBL] [Abstract][Full Text] [Related]
45. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Pullukcu H; Tasbakan M; Sipahi OR; Yamazhan T; Aydemir S; Ulusoy S Int J Antimicrob Agents; 2007 Jan; 29(1):62-5. PubMed ID: 17189097 [TBL] [Abstract][Full Text] [Related]
46. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients. Linsenmeyer K; Strymish J; Weir S; Berg G; Brecher S; Gupta K Antimicrob Agents Chemother; 2016 Feb; 60(2):1134-6. PubMed ID: 26596940 [TBL] [Abstract][Full Text] [Related]
47. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817 [TBL] [Abstract][Full Text] [Related]
48. Oral fosfomycin for treating lower urinary tract infections due to multidrug-resistant Polat M; Ozkaya-Parlakay A; Tapısız A; Kara SS; Yüksel S J Chemother; 2022 Apr; 34(2):97-102. PubMed ID: 34286658 [TBL] [Abstract][Full Text] [Related]
49. [Evaluation of the antimicrobial susceptibility of community-acquired urinary tract infection]. Passadouro R; Fonseca R; Figueiredo F; Lopes A; Fernandes C Acta Med Port; 2014; 27(6):737-42. PubMed ID: 25641289 [TBL] [Abstract][Full Text] [Related]
50. New ways of using old antibiotics in pediatrics: Focus on fosfomycin. Tran MT Pharmacotherapy; 2023 Jul; 43(7):705-712. PubMed ID: 36825460 [TBL] [Abstract][Full Text] [Related]